Exocrine Pancreatic Insufficiency Diagnostics Market Report: Market Size & Forecast 2026

The global EPI diagnostics market comprises fecal elastase testing, direct pancreatic function tests, imaging modalities, and blood-based biomarker assays that detect insufficient production of digestive enzymes. With a 2025 valuation near $3.2 billion, the market reflects growing investment in non-invasive diagnostic solutions that reduce reliance on more invasive procedures. North America and Europe currently dominate market share, supported by advanced healthcare infrastructure and higher diagnosis rates.

• •Fecal elastase-1 immunoassay remains the most widely adopted diagnostic method due to its non-invasive nature and cost-effectiveness
• •Direct function tests including the secretin stimulation test represent the clinical gold standard despite higher complexity and cost
• •Blood-based biomarkers and imaging techniques like endoscopic ultrasound are gaining adoption as complementary diagnostic tools

The increasing global prevalence of cystic fibrosis, chronic pancreatitis, and long-standing Type 1 and Type 2 diabetes serves as the primary driver of diagnostic demand, as these conditions frequently lead to EPI development. Aging populations contribute significantly as elderly patients face higher rates of pancreatic disorders and comorbidities requiring enzyme insufficiency assessment. Additionally, growing clinical awareness and updated diagnostic guidelines encourage earlier and more frequent testing across primary care and specialty settings.

• •Rising cystic fibrosis prevalence, particularly in North America and Europe, sustains demand for routine EPI screening in specialized care centers
• •Growing recognition that diabetes patients commonly develop EPI has expanded the addressable patient population beyond traditional gastroenterology settings
• •Increased surgical procedures involving the pancreas or upper gastrointestinal tract create post-operative diagnostic requirements

The market divides into in vitro diagnostic tests, imaging-based diagnostics, and point-of-care screening devices, with laboratory tests representing the largest segment. Geographically, North America leads due to high healthcare spending and established diagnostic protocols, while Asia-Pacific emerges as the fastest-growing region driven by improving healthcare access and rising disease awareness. Europe maintains substantial market presence through universal healthcare coverage supporting diagnostic utilization.

• •North America accounts for approximately 40-45% of global market share, supported by advanced laboratory infrastructure and favorable reimbursement policies
• •Asia-Pacific is projected to grow at above-market rates as developing nations expand gastroenterology services and diagnostic capabilities
• •The in vitro diagnostics segment, particularly fecal elastase testing, represents the largest product category by revenue

What are the recent trends and outlook?

Technological innovation is shifting the market toward non-invasive, rapid testing methods that can be performed in outpatient settings without specialized equipment. The integration of artificial intelligence for interpreting complex diagnostic results and identifying patterns across patient populations represents a significant emerging trend. Looking forward, the market is positioned for sustained expansion as personalized medicine approaches drive demand for precise diagnostic stratification and the aging global population increases the burden of pancreatic disorders.

• •Development of novel biomarkers beyond fecal elastase aims to improve diagnostic accuracy, particularly in early-stage or mild EPI cases
• •Point-of-care testing devices designed for primary care and home use are expected to gain market traction as miniaturization technology advances
• •Expanded screening programs targeting high-risk populations including cystic fibrosis patients and chronic pancreatitis sufferers will drive procedural volume growth